StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Krystal Biotech price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Krystal Biotech's price to sales ratio was 20.7× on Nov 11, 2026, against 16.9× a year earlier. Over the last 3 years it ranged from 10.9× to 408.8×, with a median of 21.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202620.7×+1.6
2025Dec 31, 202519.1×+0.5
2024Dec 31, 202418.7×−390.2
2023Dec 29, 2023408.8×–

More Krystal Biotech figures

See a number that looks wrong?